Intervention

antiangiogenesis therapy

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions4

Lead sponsors shown2

Clinical trials

2 shown

Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLCNCT07231575 · 2025-11-10

NOT_YET_RECRUITING

Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate CancerNCT00244920 · 2002-01-01

Common conditions

Chemo-free Therapy1 Neoadjuvant Immunotherapy1 NSCLC1 Prostate Cancer1

Leading sponsors

OHSU Knight Cancer Institute1 Sun Yat-sen University1

Trial status mix

NOT_YET_RECRUITING1

WITHDRAWN1

Phase mix

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.